Andrew D. Simmons

9.0k total citations
60 papers, 1.2k citations indexed

About

Andrew D. Simmons is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andrew D. Simmons has authored 60 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 19 papers in Molecular Biology and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andrew D. Simmons's work include PARP inhibition in cancer therapy (23 papers), Cancer Genomics and Diagnostics (10 papers) and Prostate Cancer Treatment and Research (9 papers). Andrew D. Simmons is often cited by papers focused on PARP inhibition in cancer therapy (23 papers), Cancer Genomics and Diagnostics (10 papers) and Prostate Cancer Treatment and Research (9 papers). Andrew D. Simmons collaborates with scholars based in United States, United Kingdom and France. Andrew D. Simmons's co-authors include Thomas C. Harding, Karin Jooss, Melinda VanRoey, Minh Nguyen, Guang Huan Tu, Betty Li, Rodney A. Prell, Bo Luan, Alshad S. Lalani and Kathryn Koprivnikar and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Andrew D. Simmons

59 papers receiving 1.2k citations

Peers

Countries citing papers authored by Andrew D. Simmons

Since Specialization

Citations

This map shows the geographic impact of Andrew D. Simmons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew D. Simmons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew D. Simmons more than expected).

Fields of papers citing papers by Andrew D. Simmons

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew D. Simmons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew D. Simmons. The network helps show where Andrew D. Simmons may publish in the future.

Co-authorship network of co-authors of Andrew D. Simmons

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew D. Simmons. A scholar is included among the top collaborators of Andrew D. Simmons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew D. Simmons. Andrew D. Simmons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313.	Journal of Clinical Oncology	Laurence Albigès, Robert J. Motzer et al.	5
2	LBA67 Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 study	Annals of Oncology	Neeraj Agarwal, Arun Azad et al.	4
3	Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib	Clinical Pharmacokinetics	Mingxiang Liao, Heidi Giordano et al.	8
4	659P Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2	Annals of Oncology	S. Chowdhury, Akash Patnaik et al.	2
5	Abstract 727: Comprehensive genomic profiling of >1000 plasma and tumor tissue samples from metastatic castration-resistant prostate cancer (mCRPC) patients gives insight into targeted treatment strategies	Cancer Research	Jeremy Shapiro, Ray McDermott et al.	1
6	Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor	Clinical Lung Cancer	Elena Helman, Minh Nguyen et al.	52
7	Prognostic impact of loss of heterozygosity in uterine serous carcinoma	Gynecologic Oncology	Eman Abdulfatah, Andrea Loehr et al.	0
8	ATLAS: A phase 2, open-label study of rucaparib in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).	Journal of Clinical Oncology	Petros Grivas, Kenton Wride et al.	3
9	The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)	Annals of Oncology	S. Chowdhury, Wassim Abida et al.	2
10	Inactivation of Capicua drives cancer metastasis	Nature Genetics	Ross A. Okimoto, Frank Breitenbuecher et al.	117
11	Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma	Clinical Cancer Research	Minh Nguyen, Shuichi Miyakawa et al.	19
12	Not just another paediatric neck lump: metastatic cribriform adenocarcinoma of the palate in an adolescent	The Journal of Laryngology & Otology	Arjun Takhar, Andrew D. Simmons et al.	9
13	Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity	Cancer Immunology Immunotherapy	Andrew D. Simmons, Марина Москаленко et al.	47
14	An Antibody Delivery System for Regulated Expression of Therapeutic Levels of Monoclonal Antibodies In Vivo	Molecular Therapy	Jianmin Fang, Andrew D. Simmons et al.	84
15	The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration	Cancer Immunology Immunotherapy	Rodney A. Prell, Andrew D. Simmons et al.	26
16	Efficient Tet-Dependent Expression of Human Factor IX in Vivo by a New Self-Regulating Lentiviral Vector	Molecular Therapy	Elisa Vigna, Mario Amendola et al.	54
17	Complement regulatory proteins are incorporated into lentiviral vectors and protect particles against complement inactivation	Gene Therapy	Andrew D. Simmons, Melanie J. Tuerk et al.	40
18	Physical and transcriptional map of the critical region for keratolytic winter erythema (KWE) on chromosome 8p22-p23 between D8S550 and D8S1759	European Journal of Human Genetics	Silke Appel, Matthias Filter et al.	8
19	Neurogenin2 Expression in Ventral and Dorsal Spinal Neural Tube Progenitor Cells Is Regulated by Distinct Enhancers	Developmental Biology	Andrew D. Simmons, Jane E. Johnson et al.	46
20	Physical Map and Characterization of Transcripts in the Candidate Interval for Familial Chondrocalcinosis at Chromosome 5p15.1	Genomics	Teresa D. Gallardo, Andrew D. Simmons et al.	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact